Tuberculosis vaccine.
Tuberculosis (TB) is still one of the leading causes of death from a single infectious agent, killing 1.6 million people each year, mostly in developing countries. The existing vaccines, Bacille Calmette and Guerin (BCG), are efficient in preventing the most severe disseminated forms of disease in children and newborns, but its efficacy against active TB in adults has been challenged by several clinical studies. It is a common opinion that only the development of a new and more effective vaccine against TB would significantly ease the deadly disease. In recent years, looking for a new vaccine or an improved TB vaccine is urgently needed. Such vaccines include new live and attenuated strains of Mycobacterium tuberculosis, improved recombinant BCG strains, subunit and DNA vaccines.
Sarhan
Mohammed A
MA
Department of Biological Sciences, College of Science, King Khalid University, PO Box 9004, Abha 61413, Kingdom of Saudi Arabia. mohammed_sarhan@yahoo.com
D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007231:Infant, Newborn; D032581:Tuberculosis Vaccines / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control* / Q000635:transmission; D019444:Vaccines, DNA / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D001500:BCG Vaccine; D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic